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553Reconsidering pluripotency tests: Do we still need teratoma assays?are exposed to a non-physiological environment. Since many mice are used for a result that is heavily questioned, it is time to
reconsider the teratoma assay from an ethical point of view. Candidate alternatives to the teratoma assay comprise the directed
differentiation of pluripotent stem cells into organotypic cells, differentiation of cells in embryoid bodies, the analysis of
pluripotency-associated biomarkers with high correlation to the teratoma forming potential of stem cells, predictive epigenetic
footprints, or a combination of these technologies. Each of these assays is capable of addressing one or more aspects of
pluripotency, however it is essential that these assays are validated to provide an accepted robust, reproducible alternative. In
particular, the rapidly expanding number of human induced pluripotent stem cell lines, requires the development of simple,
affordable standardized in vitro and in silico assays to reduce the number of animal experiments performed.
© 2013 Elsevier B.V. Open access under CC BY-NC-ND license.Contents
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The experimental induction of teratoma (for definition of
terms see Box 1) in mammals, mostly mice, has been carried
out for decades (Evans and Kaufman, 1981; Skreb et al., 1971;
Solter et al., 1970; Stevens, 1958, 1970; Stevens & Little,
1954). In stem cell research and banking (ISCBI, 2009) the
in vivo teratoma assay can be used to demonstrate the
pluripotency of the stem cells in vivo (Gertow et al., 2007;
Wesselschmidt, 2011). Basically stem cells, which are consid-
ered to be pluripotent, are injected into various anatomical
sites e.g. sub-cutaneous, intra-muscular, under the capsule of
the kidney, or intra-testicular, of immunocompromised mice
potentially developing into an experimental tumor (also see
Box 1). The assayed cells are considered pluripotent if
the resultant tumor shows characteristics of a teratoma,
demonstrating the development of differentiated cells from
all three germ layers, namely ectoderm (such as nerve and
skin), mesoderm (including bone, cartilage and muscle), and
endoderm (liver and gut) (Brivanlou et al., 2003).
Although used regularly and frequently demanded by
reviewers of manuscripts as proof of pluripotency, the
teratoma assay has never been standardized in terms of
graft site, age of mice, number of cells implanted and the
cell preparation for a large number of pluripotent cell lines.
These factors invariably influence the development of the
teratoma (Hentze et al., 2009; Wesselschmidt, 2011). Gropp
et al. recently presented a systematic evaluation of some ofthese factors for two ESC lines (Gropp et al., 2012). In
addition to the lack of standardization of the teratoma
assay, the assay is also regarded as time, cost and labor
intensive. The assay certainly raises ethical concerns, as it
may induce pain and suffering of the animals used in the
assay. This latter concern impacts on the current legislation
on animal welfare and the following section will give an
overview on the current status in Europe.
From the animal welfare perspective the teratoma assay
raises two major issues: first, the inoculation of genetically
manipulated animals with potentially malignant cells that
could initiate tumors, and second, the breeding of experimen-
tal animals, especially if associated with the suffering and pain
of the animal. A classification system, comprising the degree of
pain, suffering and distress, was accepted in 1995 and has been
in general use throughout Europe. This system is known as the
Severity Catalogue of the Swiss Federal Veterinary Office. In
the European Union (EU), a binding severity classification
system was approved in 2010 as Annex VIII of the new “EU
Directive 2010/63/EU for the Protection of Animals used in
Scientific Procedures” (European Union, 2010). Accordant
regulations and amendments are published by the Canadian
Council on Animal Care in Science, the Australian and New
Zealand Council for the Care of Animals in Research and
Teaching, and in the U.S.A, under the Laboratory Animal
Welfare Act.
The Swiss Catalogue considers tumor models as moderately
severe (grade 2) and severe (grade 3) procedures. The grade 2
Box 1 Explanation of terms used in this paper according to the NIH definitions.
Teratoma — a multi-layered benign tumor that grows from pluripotent cells injected into animals with a
dysfunctional immune system. Scientists test whether they have established a human embryonic stem
(hES) cell line by injecting putative stem cells into such mice and verifying that the resulting teratoma
contains cells derived from all three embryonic germ layers.
Teratocarcinoma — a multi-layered malignant tumor that contains in addition to a teratoma embryonal
carcinoma cells, which either give rise to metastases or produce a malignant tumor after re-implantation of
the primary tumor mass. The WHO recommended for this type of tumor the more complicated term
“mixed embryonal carcinoma and teratoma”. A detailed consideration of the difference between teratoma
and teratocarcinoma can be found in a series of comments in Nature Biotechnology Vol. 25, No. 11
(Damjanov and Andrews, 2007). In a teratoma assay development of this type of tumor would
immediately lead to the exclusion of the putative pluripotent stem cells from any type of therapeutical
application.
Severe combined immunodeficient (SCID) mice — SCID mice are important tools for researching
hematopoiesis, innate and adaptive immunity, autoimmunity, infectious diseases, cancer, vaccine develop-
ment, and regenerative medicine in vivo. So-called because of their severe combined immunodeficiency, SCID
mice have reduced ability to reject allogeneic or xenogeneic tissue grafts, and are therefore excellent hosts for
human cells and tissues.
Teratoma assay— in this assay putative pluripotent stem cells are implanted into SCIDmicewhere they can
proliferate and differentiate to form a teratoma. The pluripotent stem cells grow at the implantation site and
are supported by factors of the local milieu and also circulating factors. After a certain time, when the tumor
has reached sufficient size, it is removed and subjected to histopathological analysis, immunocytochemistry
and gene expression profiling.
Tetraploid complementation assay— an assay that can be used to test a stem cell's potency. Fusing two
2-cell embryos produces cells with 4 sets of chromosomes (tetraploid cells) that are biased toward
developing into extra-embryonic tissues only. The tetraploid cells are not able to generate a developmentally
competent embryo itself; however, an embryo can develop properly from “sandwiched” diploid stem cells in
case, the injected cells are pluripotent.
554 C. Buta et al.classification represents tumor models, in which the induction
or transplantation of tumors does not cause cancerous
cachexia or other progressively lethal disease, or models
which are discontinued before clinically manifest dysfunctions
occur in the animal (e.g. the tumor model in mice and rats).
Grade 3 covers tumor models that induce cancerous cachexia
or other progressive lethal diseases (Swiss Federal Veterinary
Office, 2012). Analogous classifications in the future EU
catalogue aremoderate and severe. Classification as moderate
denotes models of induction of tumors or spontaneous tumors,
that are expected to causemoderate pain, distress ormoderate
interference with normal behavior. Classification as severe
refers to models with induction of tumors, that are expected to
cause progressive lethal disease associated with long-lasting
moderate pain, distress or suffering like tumors causing
cachexia, invasive bone tumors, tumors causing metastatic
spread, and tumors that are allowed to ulcerate. Taking this
classification system into account the actual teratoma assay
depends on the implementation of humane endpoints. The
growth of one or more tumors to a typical weight of 1–2 g or
up to 10% of the body weight would classify as moderate
severity. If teratoma were allowed to grow beyond this point
severity may increase to grade 3.
In 1959, William Russell and Rex Burch classified humane
animal experimental techniques under the headings of
replacement, reduction, and refinement — now commonly
known as the three Rs. Replacement means the complete
substitution of a given animal experiment by one or several
alternative tests that, singly or taken together, will supplythe needed information, e.g. in vitro experiments, computer
modeling, analysis of expression profile, proteome and
epigenetic alterations. Reduction refers to animal numbers,
which must be kept as low as possible yet still being consistent
with the delivery of robust statistical data. Other ways of
reducing animal numbers are the avoidance of duplication of
experiments performed by other scientists, and the combina-
tion of endpoints in toxicology testing. Refinement is the
alleviation of experimental severities, e.g. animal-friendly
housing and care, use of analgesics, and in general, keeping
suffering to a minimum. This includes the setting of humane
endpoints (Russell and Burch, 1959). Nowadays, the principles
of the 3Rs are widely adopted and the concepts have been
incorporated into the legal framework on animal experi-
mentation in several countries, i.e. the German animal
welfare act and the Austrian law for animal protection
(German Animal Welfare Act, §7 and Animal Protection Act,
StF: BGBl. I Nr.80/2010, http://www.ris.bka.gv.at/Dokument.
wxe?Abfrage=BgblAuth&Dokumentnummer=BGBLA_2010_I_80
(02.27.2012)). Both the current effective EU Directive on the
Protection of Animals Used for Scientific purposes (86/609/
EEC) and its revised version (2010/63/EU), repeatedly refer to
the 3Rs (2010/63/EU, preamble 11; 27; 31; 38; 39; 48; 49; Arts.
1a; 4; 27; 38; 39; 43; 48; 58; Annexes 5 and 6). In particular,
“the use of animals for scientific or educational purposes
should […] only be considered where a non-animal alternative
is unavailable”, and “when choosing methods, the principles
of replacement, reduction and refinement should be im-
plemented through a strict hierarchy of the requirement to
555Reconsidering pluripotency tests: Do we still need teratoma assays?use alternative methods” (2010/63/EU, preamble 10; 11; 12
etc.; Art 4 http://ec.europa.eu/foods/fs/aw/aw_legislation/
scientific/86-609-eec_en.pdf).Teratoma assays — when and why?
Safety testing of transplants derived from pluripotent
stem cells
Stem cell research has developed in part from tumor
research on teratocarcinoma cell lines (Martin and Evans,
1975), therefore, the teratoma assay was originally a tumor
assay before it became a useful technique to demonstrate the
pluripotency of stem cell lines (Peterson et al., 2011). It is well
known that pluripotency and tumorigenicity are closely
related phenomena in stem cells (Knoepfler, 2009). The
teratoma assay is not only a pluripotency assay but it is also
an assay for tumorigenicity. The assay is required for the
investigation of the tumor biology of teratoma and it can also
be used to address additional questions in developmental or
tumor biology (Li et al., 2009). Experimental teratoma can,
e.g. provide insights into the in vivo development of human
tissues (Gertow et al., 2011; Müller et al., 2010). It is largely
unknown which host factors guide the tissue differentiation in
teratoma and help to create three-dimensional tissue struc-
tures. Further animal studies on these aspects of teratoma
growth will likely provide important information for the
development of new in vitro tissue differentiation protocols.
These protocols might in the end even help to replace the
teratoma assay for pluripotency testing by improved in vitro
assays.
The teratoma assay as a tumorigenicity assay is of major
importance to address safety issues of new stem cell-based
therapies or transplantation. The injection of pluripotent
stem cell lines into immunodeficient or syngeneic recipients
leads usually to growth of benign teratomas (Dressel, 2011),
however also the occurrence of teratocarcinomas (see Box 1)
that infiltrate tissues and give rise to metastases has been
reported after transplantation of some stem cell lines (Erdö
et al., 2003). The close link of pluripotency and tumorigenicity
is a major challenge for regenerative medicine since it is one
important concept of regenerative medicine to generate cells
or tissues in vitro from pluripotent stem cells that can be
transplanted to replace diseased tissues in patients. Notably,
any graft that is derived from pluripotent stem cells is at risk of
containing tumorigenic cells. Numbers of pluripotent stem
cells as low as 20 for mouse (Lawrenz et al., 2004) and 245 for
human embryonic stem cells (Hentze et al., 2009) were
reported to form tumors in immunodeficient hosts. The
comparison of these numbers illustrates the enormous chal-
lenge to provide grafts from pluripotent stem cells that do not
contain tumorigenic cells. Importantly, grafts should be free
not only of teratoma forming cells but also of other cells
leading to tumors of more restricted tissue composition or even
only tissue overgrowth (Mauritz et al., 2011). For these
reasons, the teratoma assay or transplantation protocols,
which could involve the formation of teratoma or other stem
cell-derived tumors in experimental animals, will remain
important to study the safety of new therapies that are based
on stem cells.Teratoma assays could also identify pluripotent stem cell
lines with a lower intrinsic tumorigenic risk compared to
others. Notably, the tumorigenic potential of a stem cell line
or a transplant derived from stem cells is not sufficiently
described by features of these cells. Host factors that
support tumor growth need to be identified as well as factors
that can reduce the risk of tumor formation after stem cell
transplantation therapy. These host factors could include a
number and range of factors such as hormones, growth factors,
and cytokines, interactions with the extracellular matrix and
host cells, paracrine effects of host cells, vascularization, and
provision of nutritive factors. The immune system of recipients
can contribute to the rejection of tumorigenic (Dressel et al.,
2008) but also therapeutically effective cells (Saric et al.,
2008). Therefore, how host factors influence tumor risk and the
engraftment of stem cell-derived transplants needs to be
studied in greater depth.
Some of these questions can be answered in vitro but
others will require experiments in animal hosts. As stem
cell-based therapies are developed, animal experiments will
be required to demonstrate the lack of tumorigenic
potential of these grafts before the start of clinical studies.
It is a regulatory requirement for any new therapy that
involves the transplantation of stem cell-derived grafts to
demonstrate convincingly by animal experiments that the
grafts are not at a detectable risk of tumor formation (Halme
and Kessler, 2006). In conclusion, the teratoma assay or
variations of the teratoma assay are used to address research
questions that differ from the basic assessment of the
pluripotency of stem cells and could not be answered using
alternative methods designed to assess the pluripotency of
stem cells.
The teratoma assay is used as an in vivo method to test
pluripotency of cells, namely the ability of those cells to
generate cells/tissue of all three germ layers. If the
teratoma assay is really needed to characterize a new cell
line, there is an urgent requirement to analyze the teratoma
beyond the simple identification of tissues from all three
germ layers, as this would provide a tremendous amount of
additional information, e.g. embryonic development, differ-
entiation potential, maturation status (Gertow et al., 2011).
Although some potent in vitro models exist, it must be stated
that the teratoma assays may lead to new insights into the
interaction between the host and the injected stem cells and/
or their in vivo differentiation products, which would have not
been found in an ab initio designed in vitro model (Dressel
et al., 2008).Why are teratoma assays questioned?
Despite the ‘gold standard’ status of this assay, there is little
consistency in either the methodology used or the reporting
of results. Standardization may aid stem cell researchers
to evaluate better and compare results across different
reprogramming strategies and differentiation protocols.
Unfortunately the methods used for inducing teratoma are
poorly documented, frequently only by citing other publica-
tions. Screening the literature for more than 1200 original
manuscripts that were published between 1998 and 2009 in
journals, indexed in the NCBI Medline, describing research on
hESCs, as well as 124 original articles between 2007 and 2009
556 C. Buta et al.that report on human iPSCs, revealed that the assay certainly
lacks standardization. The description of the teratoma assay
varied widely and therefore we were not able to classify them
in groups. As an example, the number of injected cells varied
from clumps of 200–300 cells to 5 million cells in different
manuscripts (Müller et al., 2010). As mentioned above, the
niche/microenvironment influences the survival and differen-
tiation of the injected pluripotent cells. It was shown that the
injection site and the grade of immunodeficiency of the host
strongly influence the survival or differentiation of cells
(Dressel, 2011).
To standardize this relatively simple assay, parameters
such as the strain of mouse used, the number of cells injected,
the passage of injected cells, the number of injections per
animal, the cell harvest method, the solution for the injection
of cells, as well as the time in vivo should be provided.
Additionally, the histomorphological analysis and the format
of the results vary across the studies. Inmost cases teratoma is
examined by classic histologicalmethods via hematoxylin/eosin
stainings, although immunohistochemistry can be helpful and
sometimes even indispensable to quantify and definitely
identify tissue types. An improvement to the teratoma assay,
if required, would be to take biopsies in order to establish a
time point at which cells of all three germ layers can be
demonstrated. At this point the assay should be terminated to
avoid the development of large tumors and prevent suffering to
the animal. It may be possible therefore to establish cell growth
and differentiation kinetics that ultimately serve to keep the
period of tumor growth to a minimum.Animal welfare and ethical concerns
The greatest disadvantage of the teratoma assay is that it
requires the use of experimental animals. According to
current legislation animal experiments must be ethically
justifiable. Such a justification is generally based on a cost–
benefit analysis, in which the suffering of the animals is to
be weighed against the potential benefits for research and
scientific significance of the results obtained. According to
Article 12 (2) of the EU Council Directive 86/609/EEC for the
protection of experimental animals the following aspects
have to be considered: “where it is planned to subject an
animal to an experiment in which it will, or may, experience
severe pain which is likely to be prolonged, that experiment
must be specifically declared and justified to, or specifically
authorized by, the authority.” The following sentence of this
article emphasizes that in case of potentially prolonged
severe pain the particular experiment, not the overall
research goal, must meet high scientific requirements:
“The authority shall take appropriate judicial or administrative
action if it is not satisfied that the experiment is of sufficient
importance for meeting the essential needs of man or animal.”
In the future, European legislation will go beyond these
demands. Article 15 (2) of EU Directive 2010/63/EU lays
down, as a general rule, “that a procedure is not performed
if it involves severe pain, suffering or distress that is likely to
be long-lasting and cannot be ameliorated.” In most countries
of the western hemisphere the teratoma assays, as animal
experiments in general, are performed in accord with these
regulations. Teratoma is not allowed to grow to an excessive
size and experiments are terminated before severe pain,suffering, or distress occurs. Nonetheless, there is a need to
find alternatives for the in vivo teratoma assay to reduce the
need for animal experimentation.
The second issue regarding animal welfare is the breeding of
immune deficient mammals, which leads to highly controver-
sial discussions in both the public and scientific communities.
Some ethicists argue that experimental animals have an
intrinsic value independent of their use by humans and that
their dignity and rights should be respected. An appreciation of
the inherent value of animals means that no genetic manipu-
lation should be carried out at all (Vorstenbosch, 1993), unless
a basic or very serious human or animal interest is involved,
which cannot be met by any other means (Verhoog, 1992).
However, many of the immune deficient mice used for
teratoma assays do not result from a genetic manipulation
but occurred as natural mutations. Nevertheless, all SCID mice
are lacking major elements of their immune system. Infections
that are not harmful to normal/healthy animals, can cause
suffering or death in SCID mice. It should be noted that SCID
mice are bred under conditions that usually prevent those
infections.
In some countries the generation of genetically modified
animals is legally restricted. For example, the German
Animal Welfare Act, Article 11b states that it is prohibited to
breed vertebrates, or to change them through procedures of
biotechnology, if this results in animals or their offspring,
lacking parts of the body or organs for species-specific use or
if they are unfit or deformed, thereby causing pain, suffering
or harm. Although animal experiments are exempted from
this restriction, the law still highlights an awareness of the
ethical problems of breeding such animals.
Alternatives to the teratoma assay — their
advantages and disadvantages
Proof of pluripotency
Stem cells exhibit some unique characteristics such as the
ability to self-renew, as well as to differentiate into cell
types of all three germ layers. They have been derived from
embryos and different sources of postnatal animals. It is
logical to classify stem cells based on their developmental
potential (Table 1). Embryonic and induced pluripotent stem
cells represent the most prominent examples of pluripotent
cells, bearing the second highest degree of developmental
potential. These cells can give rise to tissue types in vivo aswell
as in vitro, but they are not able to form the extraembryonic
trophoblast lineage (Rossant, 2008).
Attributes such as the pluripotentcy and differentiation
potential are based on experimental criteria and need to be
thoroughly addressed via functional and molecular assays.
Therefore, approaches to increase the stringency of results
should be applied. From the standpoint of developmental
biology many researchers regard in vitro differentiation e.g.
in embryoid bodies (EBs) as the least stringent functional test
of pluripotency of cultured stem cells. The generation of
teratoma is perceived as being the next level of stringency.
While these two approaches are suitable for stem cells of
animal and human origin, they are limited since they do not
test the ability of the cells to undergo normal development.
The hESCs used in these assays are regarded as pluripotent
Table 2 Alternative methods for testing the pluripotency
of stem cells.
System Assays
ES cell culture Molecular profiling by genomics,
epigenomics, proteogenomics and
glycomics.
Embryoid bodies Differentiation models assaying
spontaneous differentiation, directed
differentiation, and special assays such as
vascularization or wound healing.
In silico models Computer based models and genome wide
data sets obtained from microarrays and
next-generation sequencing.
Alternative in
vivo models
Chicken egg model.
Organotypic
models
In situ analysis such as skin models,
“stripped organ” models, and
re-aggregation/integration assays.
Table 1 The various levels of cellular developmental
potential.
Totipotency Potential to give rise to a functional organism
with all its cell lineages. In mammals
exclusively the zygote and the first four to
eight blastomeres are totipotent.
Pluripotency Potential to give rise to all somatic lineages of
the body; e.g. embryonic stem cells and
induced pluripotent stem cells.
Multipotency Ability of adult stem cells to form multiple cell
types of one lineage; e.g. hematopoietic stem
cells.
Unipotency Cells form one cell type; e.g. spermatogonial
stem cells, which at least under natural
conditions, are only able to generate sperms.
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primates to demonstrate that they are indeed pluripotent and
give rise to all the tissues. So far this functional assay can only
be demonstrated for murine and rat stem cells via chimera
formation and germ line contribution. The most stringent test
for developmental potential is achieved via the aggregation of
stem cells with tetraploid host morulae (Eggan et al., 2001;
Nagy et al., 1990). This approach results in animals exclusively
derived from the donor cells because the 4n host cells will
exclusively give rise to the trophectoderm. These “all ES” and
the recently described “all iPS” (Boland et al., 2009; Kang et
al., 2009; Stadtfeld et al., 2010; Zhao et al., 2009) embryos or
animals avoid the formation of a chimera originating from
both donor and host cells. For iPS cell lines in vitro tests
demonstrating the upregulation of endogenous pluripotency
markers as well as the silencing of the transgenes have to be
performed. The latter set of testing can be overcome using
novel non-genetic approaches for reprogramming such as RNA
or protein transfection as well as administration of small
molecules (Stadtfeld and Hochedlinger, 2010).
Potential alternatives to teratoma assays are i) the
characterization of the expression of pluripotency markers
e.g. Oct-4, Nanog, Sox2 (Fong et al., 2008; Mitsui et al.,
2003; Pesce and Scholer, 2001), ii) status of the epigenome,
iii) in vitro differentiation, either spontaneous or directed,
and iv) computer-prediction models, or combinations of
these (Table 2). The expression of pluripotency-associated
markers may provide a good initial tool to determine the
extent of pluripotency. Markers such as TRA-1-60, DNMT3B,
and REX1 correlate with the teratoma forming potential of
iPS cells (Chan et al., 2009). Yet, teratocarcinoma cell lines,
genetically abnormal hESC and iPSC cultures, as well as
epigentically irregular, e.g. partially reprogrammed cell
lines, do frequently express the same markers at comparable
levels (Chan et al., 2009; Müller et al., 2008). Although a
selected number of these expression markers may provide a
first good predictive value, these criteria are still rather
subjective and at the moment it is too early to use these as
the sole prediction criterion. Before these markers can be
generally applied as a tool to determine pluripotency a
thorough validation using many more embryonic stem cell
lines and self-renewing somatic stem cells from different
species is required. However, together with results derivedfrom more objective experiments such as in vitro differenti-
ation assays, the pluripotency state of stem cells may become
predictable.
Epigenomic footprints, such as DNA methylation and
histone modifications, may be exploited for this as was
shown in the same study (Boulting et al., 2011). Loss of
chromatin remodeling complex proteins, for example, led to
lethality at the blastocyst stage. This supposes that epigenetic
rearrangements, to keep pluripotency, need to take place
before the formation of the ICM (Cao and Zhang, 2004;
Houlard et al., 2006; Klochendler-Yeivin et al., 2000). The
dynamic nature of chromatin is specific to pluripotent cells
and upon differentiation this changes to a more structured
condensed and heterochromatic genome. Basically the eu-
chromatic pluripotent stem cells change from an acetylated
histone H3 and H4 environment to increased global levels of
trimethylated lysine 9 H3 leading to gene repression, when
cells start to differentiate (Atkinson and Armstrong, 2008;
Kimura et al., 2004; Lee et al., 2004). Promoter regions of
Nanog and Oct3/4 are enriched for acetylation of H4 and
trimethylated lysine 4 of H3, where they are active. On the
other hand thesemodifications are absent in the trophectoderm
and instead enriched formethylated lysine 9 of H3 to keep them
silent (Atkinson and Armstrong, 2008).
In vitro differentiation— directed and spontaneous
differentiation
ESCs can be induced to differentiate to most cell types via the
aggregation of ESCs in hanging drop cultures, in multi-well
plates or in suspension culture (Wobus et al., 1984). Based on
this data, more andmore examples of directed differentiation
emerge, which no longer rely on the plethora of unknown
signals, which induce differentiation in EBs. Neurospheres
containing neural stem cells can be generated and used to
study the neural differentiation program (Ferrari et al., 2010;
Studer, 2001). Cardiac bodies generated from isolated cardi-
ac stem cells give rise to cardiomyocytes, endothelial cells
and smooth muscle cells (Höbaus et al., 2013; Taubenschmid
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with high efficiency from ESCs in monolayers (Borowiak et al.,
2009; Zhu et al., 2009). Murine ESC aggregates resemble the
early embryonic development of mouse for 7 to 8 days and
spontaneously give rise to cells of ectodermal, endodermal
and mesodermal origin. Until day 8, EBs undergo a morpho-
logical development resembling early embryogenesis until
gastrulation commences (Bader et al., 2001). Later on,
differentiation and development of other cell types appear to
be chaotic so far (Weitzer, 2006). However cardiomyogenesis
seems to follow a morphological program at least until day 8 of
differentiation (Fuchs et al., 2012).
Furthermore, in EBs cellular function can be studied by
electrophysiology and cell–cell interaction can be studied by
immunofluorescence microscopy quite well; however, it
seems that in teratoma cell–cell interaction resembles the
situation in a tissue much better than in EBs and somatic
stem cell aggregates. Likewise, nutrition and blood supply in
teratoma reflect physiological conditions better than in EBs
and monolayer cultures of stem cells. In teratoma, cells of
the host, mainly the blood vessels growing into the tumor,
influence the development of the tumor and thus also
significantly influence the results obtained from expression
analysis etc. In teratoma new blood vessels supply the tissues
with nutrition and oxygen, however, in stem cell aggregates
thicker than 7 cell layers, no reproducible supply with
nutrition and oxygen exists. Thus development of an in vitro
angiogenesis model in combination with stem cell aggregation
experiments, as a possibility to improve the physiological
relevance of this model, is desirable.
In vitro models alone might be sensitive but are not
specific enough for the study of the genomics and epige-
netics of hESC or hiPSC lines. To address this problem and
the gap between in vivo and in vitro models, in silico
genome wide methods such as whole genome transcriptome
profiles in combination with complex biomarker models can
identify deviations from a defined “ideal” phenotype on a
global scale (Müller et al., 2008, 2011; Williams et al.,
2011).Computer-based predictive models
Machine-learning based models can identify signatures
characteristic of pluripotent stem cells in functional genomic
data sets (Brolen et al., 2010; Medine et al., 2010; Müller et al.,
2008) and can also highlight deviations from an “ideal”
pluripotent stem cell phenotype (Müller et al., 2011; Williams
et al., 2011). In silico assays could be a cost effective alter-
native to teratoma assays and would enable many exploratory
bioinformatic downstream applications. Current challenges,
in regard to in silico models, are i) standardization issues,
ii) acceptance in the field, iii) regulatory issues and iv) most
importantly the availability of comparable and multiple
datasets of genomic, expression profile, proteomic and epige-
netic analysis.
First, pluripotency models can be developed with reason-
able funding for one microarray platform (e.g. Illumina) but
transfer to other platforms (e.g. RNA-seq) is a resource
intensive challenge. Secondly, even as bioinformatics is be-
coming an important part in pluripotent stem cell research yet
most wet stem cell biologists have never received propertraining e.g. in using high-level bioinformatic tools such as
Bioconductor/R. Hence accessible ways of disseminating
bioinformatic assays for pluripotency to a non-expert audi-
ence have to be developed. Reliable and standardized ways
for the effective communication of such bioinformatic results
have to be agreed on by researchers, reviewers and journals,
comparable to the Minimum Information About a Microarray
Experiment (MIAME) standard required for the reporting of
microarray experiments by most peer reviewed journals
(Brazma et al., 2001). Finally, global microarray datasets
have been widely used in preclinical, exploratory analyses,
but rarely as defined outcome measure. Simple signature-
based approaches are unable to identify stochastic, random
and unexpected events regularly emerging in stem cell
cultures, such as epigenetic or even genetic alterations and
abnormalities (Williams et al., 2011). As costs for generating
high-content datasets are currently dropping below a single
day of a postdocs salary due to the next-generation sequencing
revolution, a global, genome wide and data driven approach
will become more and more attractive and highly desirable for
pluripotent stem cell research in spite of possible regulatory
challenges.
A first bioinformatic assay for pluripotency in human cells
(PluriTest) has been recently developed and published
(Müller et al., 2011) and can be used through a simple web
interface at www.pluritest.org. Up to date, more than 6200
microarray data sets have been uploaded and analyzed.
PluriTest currently supports Illumina gene expression
arrays and will be expanded to RNA-seq data in the near
future.
Chicken egg model — chorioallantoic membrane
Another option to the study of teratoma formation could be
the transplantation of stem cells onto the chorioallantoic
membrane (CAM) of avian/chicken embryos. The CAM is
situated at the periphery of the chicken embryo as a densely
vascularized extraembryonic tissue. It is easily accessible by
opening a hole in the egg shell. Experiments have been
performed some 100 years ago and this model convinces by
the ease of access and the natural immunodeficient envi-
ronment of the developing embryo. Tumor growth can be
observed within days and are of approximately 5–10 mm in
size. They have sufficient similarity to teratoma and strongly
resemble clinical specimen of patient samples (Durupt et al.,
2012; Hagedorn et al., 2005). The CAM model combines the
advantages of the in vivo environment with the simplicity of
an in vitro experiment, is cheap, fast and without serious
ethical issues.
Organotypic models
The development of an in vitromodel of teratoma formation,
such as a skin model would be of great importance, as it could
be cultured in vitro via tissue engineering, where stem cells
are injected into skin pads and allowed to develop and
differentiate. Another possibility would be to develop strat-
egies for the testing of stem cells for their repopulation
potential of cell-free organ templates. These would serve as
an ECM-template for directed differentiation. This has already
been done with hearts and human trachea, where the organ
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extracellular material, which can be repopulated by stem
cells (Ott and Taylor, 2006; Elliott et al., 2012). Further it is
possible to re-aggregate dissociated embryonic kidneys,
which were still able to form organotypic renal structures
(Unbekandt and Davies, 2010). This method was also used to
form chimeric renal structures mixing murine embryonic
kidney cells with human amniotic fluid stem cells (hAFSCs).
hAFSCs were able to integrate into and contribute to renal
structures. Using siRNA knock down technology they showed
which genes contributed to renal structure formation
(Siegel et al., 2010). This model can be used both as a
pluripotency assay and will allow us to gain new insight into
putative stem cell therapy in kidney disease models. Adult
murine ventricular slices serve as a new in vitro model of
adult myocardium with preserved in vivo structure. In the
future, these could be used to study functional integration of
stem cells transplanted in infarcted hearts in vivo (Halbach
et al., 2006).An example of differential information content
of embryoid bodies and teratoma assays
Monitoring the development of cells in EBs allows the
analyses of dynamic aspects of cell differentiation and to
identify factors which differentially affect consecutive
developmental stages of cells or simple tissues. Furthermore,
analysis of large numbers of EBs provides the basis for robust
statistical analysis of data. This type of information cannot be
obtained from histological sections of teratoma because there
is only one endpoint per teratoma available and statistical
analysis is limited by the rather small number of animals
typically used for teratoma assay. The following example will
demonstrate that the information obtained from in vitro
experiments in EBs may be more informative than that from
teratoma assays in mice.
The question, whether the absence of the histone
deacetylase 1 in stem cells influences their ability to undergo
mesenchymal-to-epithelial transition (Lagger et al., 2010),
could be more precisely and quantitatively addressed and
answered in EBs than in a mouse teratoma assay (Fig. 1). In
hdac1+/+ EBs (Fig. 1A) multiple and well structured columnar
epithelial cells develop in cysts, whereas in hdac1−/− EBs only
rudimentary structures mainly composed of small cuboidal cells
become visible. The data obtained from these experiments
have the same informational content than histological sections
obtained from teratoma in mice (Figs. 1D and E). In addition,
data from several hundred EBs demonstrate both a qualitative
and quantitative statistically significant difference in epithelial
cyst development, and finally also a delay in time required to
obtain epithelial cysts. The latter cannot be obtained from
teratoma removed and analyzed only at the end of the
experiment.
This example shows that experiments with hundreds of EBs
have a statistical significance higher than that from a few
teratoma and developmental processes can be monitored
directly. In contrast, teratoma formation provides only a
static view, can only be performed in lower numbers, is less
reproducible than stem cell aggregation, and much higher
costs accrue.Conclusions and future perspectives
Due to the extraordinary speed that stem cell research is
proceeding, scientists rarely have time to improve or replace
assay systems that are working. For industrial and clinical
applications the differentiation potential assessed by in vitro
differentiation would be sufficient, as often only one specific
cell type is needed. Therefore, if proof of pluripotency is not
essential, teratoma models should not be used. In fact,
directed differentiation of stem cells in monolayers or as EBs,
provides much more detailed information on the development
and function of those cells. The influence of growth factors,
transcription factor expression, and cytokines can be studied
on the molecular and cellular levels from the very beginning
of differentiation until terminal differentiation of a somatic
cell using the EB system. Secondly, the differentiation process
based on a standardized EB model is highly reproducible
and allows the study of molecular mechanisms guiding the
differentiation process (Barbaric et al., 2010). Studying the
transcriptional networks regulating differentiation of stem
cells in combination with the external signals and their
respective signaling pathways will help to define conditions,
that will result in the improvement of the model of directed
differentiation. This model might indicate that aggregation of
stem cells will no longer be a prerequisite for the generation
of a specific type of somatic cell. In parallel, models based on
cell–cell and cell–matrix interactions need to be established,
to provide knowledge from which more complex in vitro
models will be developed and validated for clinical, pharma-
cological, and toxicological applications (Andrews et al., 2010;
Laustriat et al., 2010).
To broaden the acceptance of in vitro as well as in silico
models as valid pluripotency tests, more research needs to be
performed on stem cell aggregates, on directed differentiation
of stem cells without prior aggregation, and global correlates
of these processes in high content formats such as RNA-seq or
Methyl-seq. It is also essential to investigate the fundamental
molecular and cellular processes taking place in EBs and
somatic stem cell aggregates. It is important to understand
these molecular and morphological changes seen in EBs and to
correlate them with bona fide embryogenesis.
There are a number of alternative in vitro approaches
available to the stem cell community for the assessment
of pluripotency. If an objective analysis of the intended
use of a cell line suggests that in vivo testing can be
excluded, the latter should be dropped altogether. There
is no ethical and academic justification to test cell lines
universally in a teratoma assay in order to generate results
that prove to be less informative than those generated by in
vitro approaches.Disclosures
The central aim of the SET Foundation is to reduce and
replace animal experimentation. The Foundation is made up
of representatives from industry, animal welfare, science
and government. Their role is the transparent, interdisci-
plinary allocation of funds to eligible projects researching
and implementing methods to replace and complement
experiments on animals (www.stiftung-set.de).
Figure 1 Development of epithelial cysts in hdac1−/− EBs and teratoma. (A to C) Wild type (hdac1+/+) and hdac1−/− ESCs were
aggregated in hanging drop cultures for 4.7 days and then plated on gelatine coated tissue culture plates. Development of epithelial cysts
was monitored between days 5 and 14. First epithelia cysts become visible between days 8 and 8.7. (A) Phase contrast images of hdac1+/+
and hdac1−/− EBs. (a and g) Overview of a typical area adjacent to the center of EBs at day 11. Long arrows, single isolated epithelial cysts.
Short arrows, large layers of epithelial cells. (b and c) Primitive epithelial cysts forming between days 8 and 9 in hdac1+/+ EBs. (d to e)
Fully developed columnar-epithelial cysts with a clearly visible lumen forming in hdac1+/+ EBs between days 10 and 12. (h and i) Early
cysts with non-epithelial small cells forming between days 8 and 9 in hdac1−/− EBs. (j and k) Samples of rarely found cysts with a lumen in
hdac1−/− EBs. Note, cells in h to k never develop to a columnar epithelial phenotype. Bars in g (for a and g), 1 mm; in k (for b to e, and h to
k), 200 μm. (B) Percentage of EBs with epithelial cysts between days 8.7 and 11.7. (C) Number of epithelial cysts per EB. Data from days
9.7 and 10.7 are from two independent triplicate experiments. Data from days 8.7 and 11.7 are from one triplicate experiment. Mean
number of EBs checked per day, 53 +/− 16. Error bars: standard deviation. (D and E) Teratoma were generated from 3 × 106 mouse
wild-type (D) and HDAC1-deficient (E) ES cells. Cells were subcutaneously injected in SCID/Balb/cmice and teratoma formation aswell as
tumor size was monitored every 4 days. Recipient SCIDmice were killed after 28 days post-injection and teratoma of both genotypes was
removed and analyzed by immunohistochemistry with HDAC2 antibodies (red). Bar in D and E: 170 μm. 3 tumors per cell linewere used for
statistical analysis and cell counts.
Panels D and E with permission from EMBO Journal adapted from Lagger et al. (2010).
560 C. Buta et al.ReferencesAndrews, P.D., Becroft, M., Aspegren, A., Gilmour, J., James, M.J.,
McRae, S., Kime, R., Allcock, R.W., Abraham, A., Jiang, Z., et al.,
2010. High-content screening of feeder-free human embryonic stem
cells to identify pro-survival small molecules. Biochem. J. 432,
21–33.
Atkinson, S., Armstrong, L., 2008. Epigenetics in embryonic stem cells:
regulation of pluripotency and differentiation. Cell Tissue Res. 331,
23–29.
Bader, A., Gruss, A., Hollrigl, A., Al-Dubai, H., Capetanaki, Y., Weitzer,
G., 2001. Paracrine promotion of cardiomyogenesis in embryoid
bodies by LIF modulated endoderm. Differentiation 68, 31–43.Barbaric, I., Gokhale, P.J., Andrews, P.W., 2010. High-content
screening of small compounds on human embryonic stem cells.
Biochem. Soc. Trans. 38, 1046–1050.
Boland, M.J., Hazen, J.L., Nazor, K.L., Rodriguez, A.R., Gifford, W.,
Martin, G., Kupriyanov, S., Baldwin, K.K., 2009. Adult mice
generated from induced pluripotent stem cells. Nature 461, 91–94.
Borowiak, M., Maehr, R., Chen, S., Chen, A.E., Tang, W., Fox, J.L.,
Schreiber, S.L., Melton, D.A., 2009. Small molecules efficiently
direct endodermal differentiation of mouse and human embryonic
stem cells. Cell Stem Cell 4, 348–358.
Boulting, G.L., Kiskinis, E., Croft, G.F., Amoroso, M.W., Oakley, D.H.,
Wainger, B.J., Williams, D.J., Kahler, D.J., Yamaki, M., Davidow, L.,
et al., 2011. A functionally characterized test set of human induced
pluripotent stem cells. Nat. Biotechnol. 29, 279–286.
561Reconsidering pluripotency tests: Do we still need teratoma assays?Brazma, A., Hingamp, P., Quackenbush, J., Sherlock, G., Spellman, P.,
Stoeckert, C., Aach, J., Ansorge, W., Ball, C.A., Causton, H.C., et
al., 2001. Minimum information about a microarray experiment
(MIAME)-toward standards for microarray data. Nat. Genet. 29,
365–371.
Brivanlou, A.H., Gage, F.H., Jaenisch, R., Jessell, T., Melton, D.,
Rossant, J., 2003. Stem cells. Setting standards for human
embryonic stem cells. Science 300, 913–916.
Brolen, G., Sivertsson, L., Bjorquist, P., Eriksson, G., Ek, M., Semb, H.,
Johansson, I., Andersson, T.B., Ingelman-Sundberg, M., Heins, N.,
2010. Hepatocyte-like cells derived from human embryonic stem
cells specifically via definitive endoderm and a progenitor stage. J.
Biotechnol. 145, 284–294.
Cao, R., Zhang, Y., 2004. The functions of E(Z)/EZH2-mediated
methylation of lysine 27 in histone H3. Curr. Opin. Genet. Dev.
14, 155–164.
Chan, E.M., Ratanasirintrawoot, S., Park, I.H., Manos, P.D., Loh,
Y.H., Huo, H., Miller, J.D., Hartung, O., Rho, J., Ince, T.A., et al.,
2009. Live cell imaging distinguishes bona fide human iPS cells
from partially reprogrammed cells. Nat. Biotechnol. 27,
1033–1037.
Damjanov, I., Andrews, P.W., 2007. The terminology of teratocarci-
nomas and teratomas. Nat. Biotechnol. 25, 1212 (discussion 1212).
Dressel, R., 2011. Effects of histocompatibility and host immune
responses on the tumorigenicity of pluripotent stem cells.
Semin. Immunopathol. 33, 573–591.
Dressel, R., Schindehutte, J., Kuhlmann, T., Elsner, L., Novota, P.,
Baier, P.C., Schillert, A., Bickeboller, H., Herrmann, T.,
Trenkwalder, C., et al., 2008. The tumorigenicity of mouse
embryonic stem cells and in vitro differentiated neuronal cells is
controlled by the recipients' immune response. PLoS One 3,
e2622.
Durupt, F., Koppers-Lalic, D., Balme, B., Budel, L., Terrier, O.,
Lina, B., Thomas, L., Hoeben, R.C., Rosa-Calatrava, M., 2012.
The chicken chorioallantoic membrane tumor assay as model
for qualitative testing of oncolytic adenoviruses. Cancer Gene
Ther. 19, 58–68.
Eggan, K., Akutsu, H., Loring, J., Jackson-Grusby, L., Klemm, M.,
Rideout III, W.M., Yanagimachi, R., Jaenisch, R., 2001. Hybrid
vigor, fetal overgrowth, and viability of mice derived by nuclear
cloning and tetraploid embryo complementation. Proc. Natl.
Acad. Sci. U. S. A. 98, 6209–6214.
Elliott, M.J., De Coppi, P., Speggiorin, S., Roebuck, D., Butler, C.R.,
Samuel, E., Crowley, C., McLaren, C., Fierens, A., Vondrys, D.,
Cochrane, L., Jephson, C., Janes, S., Beaumont, N.J., Cogan, T.,
Bader, A., Seifalian, A.M., Hsuan, J.J., Lowdell, M.W., Birchall,
M.A., 2012. Stem-cell-based, tissue engineered tracheal re-
placement in a child: a 2-year follow-up study. Lancet 380,
994–1000.
Erdö, F., Buhrle, C., Blunk, J., Hoehn, M., Xia, Y., Fleischmann, B.,
Focking, M., Kustermann, E., Kolossov, E., Hescheler, J., et al.,
2003. Host-dependent tumorigenesis of embryonic stem cell
transplantation in experimental stroke. J. Cereb. Blood Flow
Metab. 23, 780–785.
European Union, T.E.P.a.t.c.o.t., 2010. Directive 2010/63/EU on
the protection of animals used for scientific purposes. Off. J.
Eur. Union L276, 33–79.
Evans, M.J., Kaufman, M.H., 1981. Establishment in culture of
pluripotential cells from mouse embryos. Nature 292, 154–156.
Ferrari, D., Binda, E., De Filippis, L., Vescovi, A.L., 2010. Isolation
of neural stem cells from neural tissues using the neurosphere
technique. Curr. Protoc. Stem Cell Biol. (Chapter 2, Unit 2D 6).
Fong, H., Hohenstein, K.A., Donovan, P.J., 2008. Regulation of self-
renewal and pluripotency by Sox2 in human embryonic stem
cells. Stem Cells 26, 1931–1938.
Fuchs, C., Scheinast, M., Pasteiner, W., Lagger, S., Hofner, M.,
Hoellrigl, A., Schultheis, M., Weitzer, G., 2012. Self-organization
phenomena in embryonic stem cell-derived embryoid bodies: axisformation and breaking of symmetry during cardiomyogenesis.
Cells Tissues Organs 195, 377–391.
Gertow, K., Przyborski, S., Loring, J.F., Auerbach, J.M., Epifano, O.,
Otonkoski, T., Damjanov, I., Ahrlund-Richter, L., 2007. Isolation
of human embryonic stem cell-derived teratomas for the
assessment of pluripotency. Curr. Protoc. Stem Cell Biol. (Chapter
1, Unit 1B 4).
Gertow, K., Cedervall, J., Jamil, S., Ali, R., Imreh, M.P., Gulyas, M.,
Sandstedt, B., Ahrlund-Richter, L., 2011. Early events in
xenograft development from the human embryonic stem cell
line HS181—resemblance with an initial multiple epiblast
formation. PLoS One 6, e27741.
Gropp, M., Shilo, V., Vainer, G., Gov, M., Gil, Y., Khaner, H.,
Matzrafi, L., Idelson, M., Kopolovic, J., Zak, N.B., et al., 2012.
Standardization of the teratoma assay for analysis of pluripotency
of human ES cells and biosafety of their differentiated progeny.
PLoS One 7, e45532.
Hagedorn, M., Javerzat, S., Gilges, D., Meyre, A., de Lafarge, B.,
Eichmann, A., Bikfalvi, A., 2005. Accessing key steps of human
tumor progression in vivo by using an avian embryo model. Proc.
Natl. Acad. Sci. U. S. A. 102, 1643–1648.
Halbach, M., Pillekamp, F., Brockmeier, K., Hescheler, J., Müller-
Ehmsen, J., Reppel, M., 2006. Ventricular slices of adult mouse
hearts—a new multicellular in vitro model for electrophysiological
studies. Cell. Physiol. Biochem. 18, 1–8.
Halme, D.G., Kessler, D.A., 2006. FDA regulation of stem-cell-based
therapies. N. Engl. J. Med. 355, 1730–1735.
Hentze, H., Soong, P.L., Wang, S.T., Phillips, B.W., Putti, T.C.,
Dunn, N.R., 2009. Teratoma formation by human embryonic
stem cells: evaluation of essential parameters for future safety
studies. Stem Cell Res. 2, 198–210.
Houlard, M., Berlivet, S., Probst, A.V., Quivy, J.P., Hery, P.,
Almouzni, G., Gerard, M., 2006. CAF-1 is essential for hetero-
chromatin organization in pluripotent embryonic cells. PLoS Genet.
2, e181.
Höbaus, J., Heher, P., Gottschamel, T., Scheinast, M., Auner, H.,
Walder, D., Wiedner, M., Taubenschmid, J., Miksch, M., Sauer,
T., et al., 2013. Embryonic stem cells facilitate the isolation of
persistent clonal cardiovascular progenitor cell lines and
leukemia inhibitor factor maintains their self-renewal and
myocardial differentiation potential in vitro. Cells Tissues
Organs 197, 249–268.
ISCBI, T.I.S.C.B.I., 2009. Consensus guidance for banking and supply
of human embryonic stem cell lines for research purposes. Stem
Cell Rev. 5, 301–314.
Kang, L., Wang, J., Zhang, Y., Kou, Z., Gao, S., 2009. iPS cells can
support full-term development of tetraploid blastocyst-
complemented embryos. Cell Stem Cell 5, 135–138.
Kimura, H., Tada, M., Nakatsuji, N., Tada, T., 2004. Histone code
modifications on pluripotential nuclei of reprogrammed somatic
cells. Mol. Cell. Biol. 24, 5710–5720.
Klochendler-Yeivin, A., Fiette, L., Barra, J., Muchardt, C., Babinet, C.,
Yaniv, M., 2000. Themurine SNF5/INI1 chromatin remodeling factor
is essential for embryonic development and tumor suppression.
EMBO Rep. 1, 500–506.
Knoepfler, P.S., 2009. Deconstructing stem cell tumorigenicity: a
roadmap to safe regenerative medicine. Stem Cells 27, 1050–1056.
Lagger, S., Meunier, D., Mikula, M., Brunmeir, R., Schlederer, M.,
Artaker, M., Pusch, O., Egger, G., Hagelkruys, A., Mikulits, W.,
et al., 2010. Crucial function of histone deacetylase 1 for
differentiation of teratomas in mice and humans. EMBO J. 29,
3992–4007.
Laustriat, D., Gide, J., Peschanski, M., 2010. Human pluripotent
stem cells in drug discovery and predictive toxicology. Biochem.
Soc. Trans. 38, 1051–1057.
Lawrenz, B., Schiller, H., Willbold, E., Ruediger, M., Muhs, A., Esser, S.,
2004. Highly sensitive biosafety model for stem-cell-derived grafts.
Cytotherapy 6, 212–222.
562 C. Buta et al.Lee, J.H., Hart, S.R., Skalnik, D.G., 2004. Histone deacetylase
activity is required for embryonic stem cell differentiation.
Genesis 38, 32–38.
Li, Z., Huang, H., Boland, P., Dominguez, M.G., Burfeind, P., Lai, K.M.,
Lin, H.C., Gale, N.W., Daly, C., Auerbach, W., et al., 2009.
Embryonic stem cell tumor model reveals role of vascular
endothelial receptor tyrosine phosphatase in regulating Tie2
pathway in tumor angiogenesis. Proc. Natl. Acad. Sci. U. S. A.
106, 22399–22404.
Martin, G.R., Evans, M.J., 1975. Differentiation of clonal lines of
teratocarcinoma cells: formation of embryoid bodies in vitro.
Proc. Natl. Acad. Sci. U. S. A. 72, 1441–1445.
Mauritz, C., Martens, A., Rojas, S.V., Schnick, T., Rathert, C.,
Schecker, N., Menke, S., Glage, S., Zweigerdt, R., Haverich, A.,
et al., 2011. Induced pluripotent stem cell (iPSC)-derived Flk-1
progenitor cells engraft, differentiate, and improve heart
function in a mouse model of acute myocardial infarction. Eur.
Heart J. 32, 2634–2641.
Medine, C.N., Greenhough, S., Hay, D.C., 2010. Role of stem-cell-
derived hepatic endoderm in human drug discovery. Biochem.
Soc. Trans. 38, 1033–1036.
Mitsui, K., Tokuzawa, Y., Itoh, H., Segawa, K., Murakami, M.,
Takahashi, K., Maruyama, M., Maeda, M., Yamanaka, S., 2003.
The homeoprotein Nanog is required for maintenance of
pluripotency in mouse epiblast and ES cells. Cell 113, 631–642.
Müller, F.J., Laurent, L.C., Kostka, D., Ulitsky, I., Williams, R., Lu, C.,
Park, I.H., Rao, M.S., Shamir, R., Schwartz, P.H., et al., 2008.
Regulatory networks define phenotypic classes of human stem cell
lines. Nature 455, 401–405.
Müller, F.J., Goldmann, J., Loser, P., Loring, J.F., 2010. A call to
standardize teratoma assays used to define human pluripotent cell
lines. Cell Stem Cell 6, 412–414.
Müller, F.J., Schuldt, B.M., Williams, R., Mason, D., Altun, G.,
Papapetrou, E.P., Danner, S., Goldmann, J.E., Herbst, A.,
Schmidt, N.O., et al., 2011. A bioinformatic assay for pluripotency
in human cells. Nat. Methods 8, 315–317.
Nagy, A., Gocza, E., Diaz, E.M., Prideaux, V.R., Ivanyi, E., Markkula, M.,
Rossant, J., 1990. Embryonic stem cells alone are able to support
fetal development in the mouse. Development 110, 815–821.
Ott, H.C., Taylor, D.A., 2006. From cardiac repair to cardiac
regeneration—ready to translate? Expert Opin. Biol. Ther. 6,
867–878.
Pesce, M., Scholer, H.R., 2001. Oct-4: gatekeeper in the beginnings
of mammalian development. Stem Cells 19, 271–278.
Peterson, S.E., Tran, H.T., Garitaonandia, I., Han, S., Nickey, K.S.,
Leonardo, T., Laurent, L.C., Loring, J.F., 2011. Teratoma genera-
tion in the testis capsule. J. Vis. Exp. e3177 (http://www.jove.com/
video/3177/teratoma-generation-in-the-testis-capsule).
Rossant, J., 2008. Stem cells and early lineage development. Cell
132, 527–531.
Russell, W.M.S., Burch, R.L., 1959. The Principles of Humane
Experimental Technique. Methuen, London.
Saric, T., Frenzel, L.P., Hescheler, J., 2008. Immunological barriers to
embryonic stem cell-derived therapies. Cells Tissues Organs 188,
78–90.
Siegel, N., Rosner, M., Unbekandt, M., Fuchs, C., Slabina, N.,
Dolznig, H., Davies, J.A., Lubec, G., Hengstschlager, M., 2010.Contribution of human amniotic fluid stem cells to renal
tissue formation depends on mTOR. Hum. Mol. Genet. 19,
3320–3331.
Skreb, N., Svajger, A., Levak-Svajger, B., 1971. Growth and
differentiation of rat egg-cylinders under the kidney capsule.
J. Embryol. Exp. Morphol. 25, 47–56.
Solter, D., Skreb, N., Damjanov, I., 1970. Extrauterine growth of
mouse egg-cylinders results in malignant teratoma. Nature 227,
503–504.
Stadtfeld, M., Hochedlinger, K., 2010. Induced pluripotency: history,
mechanisms, and applications. Genes Dev. 24, 2239–2263.
Stadtfeld, M., Apostolou, E., Akutsu, H., Fukuda, A., Follett, P.,
Natesan, S., Kono, T., Shioda, T., Hochedlinger, K., 2010.
Aberrant silencing of imprinted genes on chromosome 12qF1 in
mouse induced pluripotent stem cells. Nature 465, 175–181.
Stevens, L.C., 1958. Studies on transplantable testicular teratomas
of strain 129 mice. J. Natl. Cancer Inst. 20, 1257–1275.
Stevens, L.C., 1970. The development of transplantable teratocarci-
nomas from intratesticular grafts of pre- and postimplantation
mouse embryos. Dev. Biol. 21, 364–382.
Stevens, L.C., Little, C.C., 1954. Spontaneous testicular teratomas in
an inbred strain of mice. Proc. Natl. Acad. Sci. U. S. A. 40,
1080–1087.
Studer, L., 2001. Stem cells with brainpower. Nat. Biotechnol. 19,
1117–1118.
Swiss Federal Veterinary Office (Hsrg), 2012. Classification of
Animal Experiments according to Grades of Severity prior to
the Experiment (Stress Categories). (http://www.tierversuch.
ch/show=AWLaw&nav_id4104&lang=en (02.14.2012)).
Taubenschmid, J., Weitzer, G., 2012. Mechanisms of cardiogenesis
in cardiovascular progenitor cells. Int. Rev. Cell Mol. Biol. 293,
195–267.
Unbekandt, M., Davies, J.A., 2010. Dissociation of embryonic
kidneys followed by reaggregation allows the formation of
renal tissues. Kidney Int. 77, 407–416.
Verhoog, H., 1992. The concept of intrinsic value and transgenic
animals. J. Agric. Ethics 5, 147–160.
Vorstenbosch, J., 1993. The concept of integrity. Its significance for
the ethical discussion on biotechnology and animals. Livest.
Prod. Sci. 36, 109–112.
Weitzer, G., 2006. Embryonic stem cell-derived embryoid bodies: an
in vitro model of eutherian pregastrulation development and
early gastrulation. Handb. Exp. Pharmacol. 21–51.
Wesselschmidt, R.L., 2011. The teratoma assay: an in vivo
assessment of pluripotency. Methods Mol. Biol. 767, 231–241.
Williams, R., Schuldt, B., Müller, F.J., 2011. A guide to stem cell
identification: progress and challenges in system-wide predictive
testing with complex biomarkers. Bioessays 33, 880–890.
Wobus, A.M., Holzhausen, H., Jakel, P., Schoneich, J., 1984.
Characterization of a pluripotent stem cell line derived from a
mouse embryo. Exp. Cell Res. 152, 212–219.
Zhao, X.Y., Li, W., Lv, Z., Liu, L., Tong, M., Hai, T., Hao, J., Guo, C.L.,
Ma, Q.W., Wang, L., et al., 2009. iPS cells produce viable mice
through tetraploid complementation. Nature 461, 86–90.
Zhu, S., Wurdak, H., Wang, J., Lyssiotis, C.A., Peters, E.C., Cho, C.Y.,
Wu, X., Schultz, P.G., 2009. A small molecule primes embryonic
stem cells for differentiation. Cell Stem Cell 4, 416–426.
